Highlights Newsletter 1
This newsletter presents you the following key sessions:
1. Deep and rapid responses with a dexamethasone-sparing combination of daratumumab and lenalidomide in
elderly patients with multiple myeloma
2. The TRIANGLE trial supports ibrutinib as part of the first-line treatment for transplant-eligible mantle cell
lymphoma
3. Significant benefit from the addition of isatuximab to carfilzomib-dexamethasone irrespective of the time to
relapse on prior therapy in patients with relapse/refractory multiple myeloma
4. Liso-cel as a preferred second line treatment for patients with primary refractory or early relapsed LBCL
5. Blinatumomab with consolidation chemotherapy prolongs the overall survival of patients with MRD-negative
B-Cell ALL


